Occupational Allergies to Cannabis

Decuyper, Ine I.; Green, Brett J.; Sussman, Gordon; Ebo, Didier G.; Silvers, William S.; Pacheco, Karin; King, Bradley; Cohn, John R.; Zeiger, Robert S.; Zeiger, Joanna S.; Naimi, David R.; Beezhold, Donald H.; Nayak, Ajay P.

doi:10.1016/j.jaip.2020.09.003

Cited by 19 publications

(31 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Cannabis use varies with age in most studies, with younger people using cannabis more often than older individuals, a pattern overserved in the present study (Table 1); over half the cannabis users in the present study were ≥40 years, and 40% were greater than 50 years, which could be driving the prevalence of use in the present study. 38,42 Although the present population is potentially at higher risk for adverse effects to cannabis 14,43,44 and increased risk for cough, wheeze, and asthma exacerbations 16,45 , the positive effects of cannabis were more prevalent than adverse effects. A factor analysis of the positive and adverse effects revealed three factors, a single 10-item positive factor which encompassed items such as decreased pain, improved sleep and decreased anxiety, a four-item adverse factor that was comprised of nasal and cardiovascular symptoms, and a five-item adverse factor that contained cough, wheeze, and shortness of breath.…”

Section: Discussionmentioning

confidence: 88%

Cannabis attitudes and patterns of use among followers of the Allergy & Asthma Network

Zeiger¹,

Silvers

Winders³

et al. 2021

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

Cannabis attitudes and patterns of use among followers of the Allergy & Asthma Network

Zeiger¹,

Silvers

Winders³

et al. 2021

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

“…A study by Decuyper et al observed negative immunological tests in a cohort of police officers with respiratory and/or cutaneous symptoms from occupational cannabis exposure, and concluded that non-immune reactions could be a pathway for the reported symptoms (33). Clinician education as to the hazardous nature of occupational cannabis exposure and the development of cannabis-specific diagnostic tests would help to improve the diagnosis and treatment for cannabis industry workers (14,34). Further research is needed to define the workplace exposures, symptoms, and clinical respiratory disease in these workers.…”

Section: Discussionmentioning

confidence: 99%

Surveillance of work-related asthma including the emergence of a cannabis-associated case series in Washington State

2021

View full text Add to dashboard Cite

Objective: We conducted surveillance for work-related asthma (WRA) in Washington State to identify the industry sectors and asthma exposures most commonly affecting injured workers and in need of prevention activities.Methods: Using workers' compensation data as the primary data source, valid cases were classified as work-aggravated asthma (WAA) or new onset asthma that includes occupational asthma (OA) and reactive airways dysfunction syndrome (RADS). The source of exposure that caused the worker's asthma, their industry and occupation were determined.Results: There were 784 valid work-related asthma cases identified for the period 2009 -2016, WAA (n=529) was most common followed by occupational asthma (n=127) and RADS (n=12). The Health Care and Social Assistance industry had the highest number of cases (n=170) with 82% classified as WAA. The highest overall proportions of new onset asthma are occurring in Agriculture, Forestry, Fishing and Hunting (33% of work related asthma cases), Manufacturing (31%) and Construction (30%). The leading substances associated with new onset asthma across all industries include hop plant dust, wood and cedar dust, mineral and inorganic dust, mold, and cleaning materials. We describe ten cases of cannabis-associated asthma including seven from workers in the legalized cannabis industry, four of whom had OA. Conclusion:State-based work-related asthma surveillance is critical in identifying the workers and exposures associated with this occupational disease, including the detection of a case-series in the cannabis industry.

show abstract

“…Kumar et al successfully adopted subcutaneous immunotherapy to reduce a patient's symptoms of allergic rhinitis and asthma 131 . With increasing legalization likely to entail a rise of cannabis sativa use, and consequent increasing occupational exposure, safe desensitization and/or tolerance induction protocols need to be developed 12,13,126 …”

Section: Management Strategiesmentioning

confidence: 99%

“…First described 50 years ago, allergic reactions to cannabis can present with symptoms of rhinitis, conjunctivitis, asthma, cutaneous reactions due to industrial contact and anaphylaxis to hemp seed 10–12 . As well as exposure through ingestion, inhalation, or skin contact, cannabis can also provoke occupational allergies 13 …”

Section: Introductionmentioning

confidence: 99%

“…[10][11][12] As well as exposure through ingestion, inhalation, or skin contact, cannabis can also provoke occupational allergies. 13 Rising consumption underlines the need for greater awareness of the spectrum of cannabis allergy, its diagnosis and management. In recognition of this unmet need, members of the American College of Asthma Allergy and Immunology (ACAAI), the European Academy of Allergy and Clinical Immunology (EAACI) and the Canadian Society of Allergy and Clinical Immunology (CSACI) formed a joint Cannabis Allergy Interest Group (CAIG) (Appendix I in Appendix S1).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabis‐related allergies: An international overview and consensus recommendations

Skypala

Jeimy

Brucker³

et al. 2022

Allergy

Self Cite

View full text Add to dashboard Cite

Cannabis is the most widely used recreational drug in the world. Cannabis sativa and Cannabis indica have been selectively bred to develop their psychoactive properties. The increasing use in many countries has been accelerated by the COVID‐19 pandemic. Cannabis can provoke both type 1 and type 4 allergic reactions. Officially recognized allergens include a pathogenesis‐related class 10 allergen, profilin, and a nonspecific lipid transfer protein. Other allergens may also be relevant, and recognition of allergens may vary between countries and continents. Cannabis also has the potential to provoke allergic cross‐reactions to plant foods. Since cannabis is an illegal substance in many countries, research has been hampered, leading to challenges in diagnosis since no commercial extracts are available for testing. Even in countries such as Canada, where cannabis is legalized, diagnosis may rely solely on the purchase of cannabis for prick‐to‐prick skin tests. Management consists of avoidance, with legal issues hindering the development of other treatments such as immunotherapy. Education of healthcare professionals is similarly lacking. This review aimed to summarize the current status of cannabis allergy and proposes recommendations for the future management of this global issue.

show abstract

Occupational Allergies to Cannabis

Cited by 19 publications

References 58 publications

Cannabis attitudes and patterns of use among followers of the Allergy & Asthma Network

Cannabis attitudes and patterns of use among followers of the Allergy & Asthma Network

Surveillance of work-related asthma including the emergence of a cannabis-associated case series in Washington State

Cannabis‐related allergies: An international overview and consensus recommendations

Contact Info

Product

Resources

About